FITC标记的骨保护蛋白配体/破骨细胞分化因子抗体
产品名称： FITC标记的骨保护蛋白配体/破骨细胞分化因子抗体
英文名称： Anti-RANKL/CD254/FITC
产品编号： HZ-20647R-FITC
产品价格： null
产品产地： 中国/上海
品牌商标： HZbscience
更新时间： 2023-08-17T10:24:20
使用范围： ICC=1:50-200 IF=1:50-200
上海沪震实业有限公司
- 联系人 : 鲍丽雯
- 地址 : 上海市闵行区闵北路88弄1-30号第22幢AQ136室
- 邮编 : 200612
- 所在区域 : 上海
- 电话 : 139****0749 点击查看
- 传真 : 点击查看
- 邮箱 : www.shzbio.net
- 二维码 : 点击查看
Rabbit Anti-RANKL/CD254/FITC Conjugated antibody
FITC标记的骨保护蛋白配体/破骨细胞分化因子抗体
| 英文名称 | Anti-RANKL/CD254/FITC |
| 中文名称 | FITC标记的骨保护蛋白配体/破骨细胞分化因子抗体 |
| 别 名 | OPGL; CD254; hRANKL2; ODF; OPGL; Osteoclast differentiation factor; Osteoprotegerin ligand; RANKL; Receptor activator of nuclear factor kappa B ligand; sOdf; SOFA; TNF related activation induced cytokine; TNFSF 11; TNFSF11; TRANCE; Tumor necrosis factor ligand superfamily member 11; Osteoprotegerin Ligand; TNF11_HUMAN. |
| 规格价格 | 100ul/2980元 购买 大包装/询价 |
| 说 明 书 | 100ul |
| 研究领域 | 肿瘤 细胞生物 免疫学 发育生物学 |
| 抗体来源 | Rabbit |
| 克隆类型 | Polyclonal |
| 交叉反应 | Human, Mouse, Rat, Dog, Horse, Rabbit, |
| 产品应用 | ICC=1:50-200 IF=1:50-200 not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 35kDa |
| 性 状 | Lyophilized or Liquid |
| 浓 度 | 2mg/1ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human RANKL/CD254 |
| 亚 型 | IgG |
| 纯化方法 | affinity purified by Protein A |
| 储 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存条件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 产品介绍 | background: This gene encodes a member of the tumor necrosis factor (TNF) cytokine family which is a ligand for osteoprotegerin and functions as a key factor for osteoclast differentiation and activation. This protein was shown to be a dentritic cell survival factor and is involved in the regulation of T cell-dependent immune response. T cell activation was reported to induce expression of this gene and lead to an increase of osteoclastogenesis and bone loss. This protein was shown to activate antiapoptotic kinase AKT/PKB through a signaling complex involving SRC kinase and tumor necrosis factor receptor-associated factor (TRAF) 6, which indicated this protein may have a role in the regulation of cell apoptosis. Targeted disruption of the related gene in mice led to severe osteopetrosis and a lack of osteoclasts. The deficient mice exhibited defects in early differentiation of T and B lymphocytes, and failed to form lobulo-alveolar mammary structures during pregnancy. Two alternatively spliced transcript variants have been found. [provided by RefSeq, Jul 2008]. Function: Cytokine that binds to TNFRSF11B/OPG and to TNFRSF11A/RANK. Osteoclast differentiation and activation factor. Augments the ability of dendritic cells to stimulate naive T-cell proliferation. May be an important regulator of interactions between T-cells and dendritic cells and may play a role in the regulation of the T-cell-dependent immune response. May also play an important role in enhanced bone-resorption in humoral hypercalcemia of malignancy. Subcellular Location: Cytoplasm; Secreted and Cell membrane. Tissue Specificity: Highest in the peripheral lymph nodes, weak in spleen, peripheral blood Leukocytes, bone marrow, heart, placenta, skeletal muscle, stomach and thyroid. Post-translational modifications: The soluble form of isoform 1 derives from the membrane form by proteolytic processing. The cleavage may be catalyzed by ADAM17. DISEASE: Defects in TNFSF11 are the cause of osteopetrosis autosomal recessive type 2 (OPTB2) [MIM:259710]; also known as osteoclast-poor osteopetrosis. Osteopetrosis is a rare genetic disease characterized by abnormally dense bone, due to defective resorption of immature bone. The disorder occurs in two forms: a severe autosomal recessive form occurring in utero, infancy, or childhood, and a benign autosomal dominant form occurring in adolescence or adulthood. Autosomal recessive osteopetrosis is usually associated with normal or elevated amount of non-functional osteoclasts. OPTB2 is characterized by paucity of osteoclasts, suggesting a molecular defect in osteoclast development. Similarity: Belongs to the tumor necrosis factor family. Database links: Entrez Gene: 8600 Human Entrez Gene: 21943 Mouse Omim: 602642 Human SwissProt: O14788 Human SwissProt: O35235 Mouse Unigene: 333791 Human Unigene: 249221 Mouse Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. OPGL骨保护蛋白配体又称骨保护素配体(破骨细胞发育刺激因子)。属肿瘤坏死因子TNF-a家族。 OPGL促进破骨细胞的分化和活性,而OPG抑制这些过程。骨髓瘤细胞影响骨髓中这两种蛋白的生理平衡，是发生溶骨性病变的根本所在 |
该基因编码肿瘤坏死因子（TNF）细胞因子家族的成员，TNF是骨保护素的配体，是破骨细胞分化和活化的关键因子。该蛋白是树突状细胞存活因子，参与调节T细胞依赖的免疫应答。据报道，T细胞活化可诱导该基因的表达，并导致破骨细胞生成和骨丢失的增加。该蛋白通过涉及SRC激酶和肿瘤坏死因子受体相关因子（TRAF）6的信号复合物激活抗凋亡激酶AKT/PKB，表明该蛋白可能在细胞凋亡的调节中起作用。在小鼠中靶向性破坏相关基因导致严重的骨质疏松症和缺乏破骨细胞。缺失小鼠在妊娠期T淋巴细胞和B淋巴细胞的早期分化存在缺陷，未能形成小叶-肺泡乳房结构。已经发现两个交替剪接转录变体。